注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Savara Inc是一家临床阶段的生物制药公司。该公司专注于罕见的呼吸道疾病。该公司的主要项目molgramostim雾化液(molgramastim)是一种吸入性生物制剂,是一种粒细胞-巨噬细胞集落刺激因子(GM-CSF),用于自身免疫性肺泡蛋白沉积症(aPAP)的III期开发。Molgramostim是重组人GM-CSF的吸入制剂,正在开发用于治疗aPAP。肺泡蛋白沉积症(PAP)是一种罕见的肺部疾病,其特征是肺泡或气囊中表面活性剂的积聚。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Joseph S. McCracken | 71 | 2013 | Lead Independent Director |
Francesco Bonella | - | - | Member of Clinical Advisory Board |
Matthew Pauls | 53 | 2017 | Chairman & CEO |
Nevan Charles Elam | 57 | 2009 | Independent Director |
Richard J. Hawkins | 75 | 2010 | Independent Director |
David A. Ramsay | 59 | 2017 | Independent Director |
Yoshikazu Inoue | - | - | Member of Clinical Advisory Board |
Bruce C. Trapnell | - | - | Member of Clinical Advisory Board |
Tisha Wang | - | 2023 | Member of Clinical advisory Board |
Cormac McCarthy | - | 2021 | Member of Clinical Advisory Board |
An van Es-Johansson | 64 | 2019 | Independent Director |
Ricky Lijing Sun | 50 | 2019 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核